By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...

Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

Pfizer Inc. (NYSE:PFE) is included among the 15 Cheapest Stocks with Highest Dividends. On April 1, Reuters reported that a ...

Pfizer (PFE) stock and BioNTech (BNTX) stock are in focus as a large U.S. trial for the companies' updated COVID-19 vaccine ...

The move comes as COVID vaccine ‌makers grapple ‌with pushback from the U.S. administration and weak U.S. demand for the ...

BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at ...

On the heels of a comprehensive review, BioNTech has decided “to close its planned Singapore site by the end of February 2027 ...

The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...

Pfizer and BioNTech have stopped their large U.S. COVID-19 vaccine trial in adults aged 50 to 64, citing insufficient ...